EBV Immortalization of B Cells Using Polyclonal Activators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing human monoclonal antibodies, such as the EBV-based method, face limitations including low efficiency of immortalization, low cloning efficiency, slow growth rate, and low antibody production, making them inefficient for generating human monoclonal antibodies with desired antigen specificity.
Innovation Solution
The use of polyclonal B cell activators, such as CpG sequences, enhances the efficiency of EBV immortalization and cloning of human B memory lymphocytes, allowing for the rapid isolation of human monoclonal antibodies from the memory repertoire without the need for specific immunization or boosting, thereby enabling the production of antibodies with desired antigen specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If EBV is used to immortalize human B cells, then antibody production is enabled, but immortalization efficiency is low
Solution Approach 1:
The patent applies preliminary action by pre-activating B cells with polyclonal activators (such as anti-CD40 antibodies, LPS, or other mitogens) before EBV infection. This preliminary activation puts B cells in a more permissive state for EBV transformation, thereby increasing immortalization efficiency while maintaining antibody production capability
Solution Approach 2:
The patent changes the physiological state parameters of B cells by controlling activation conditions (using different polyclonal activators, adjusting cell density, incubation time, and culture conditions) to optimize both immortalization efficiency and subsequent antibody production
2Reliability
If EBV immortalization is performed without polyclonal activators, then process simplicity is maintained, but cloning efficiency is low
Solution Approach 1:
The patent uses polyclonal activators as a preliminary step before EBV infection to enhance B cell responsiveness and transformation efficiency. This additional step significantly improves cloning efficiency (obtaining stable antibody-producing clones) while keeping the overall process relatively simple and scalable
3Speed
If conventional EBV methods are used, then human monoclonal antibodies can be produced, but growth rate is slow
Solution Approach 1:
By pre-activating B cells with polyclonal activators before EBV transformation, the patent generates immortalized B cell lines with enhanced growth characteristics. These pre-activated cells exhibit faster proliferation rates while maintaining their antibody production capacity, thus resolving the contradiction between growth rate and productivity
Data Source
AI summary
A method for producing a clone of an immortalized human B memory lymphocyte, comprising the step of transforming human B memory lymphocytes using Epstein Barr Virus (EBV) in the presence of a polyclonal B cell activator. The method is particularly useful in a method for producing a clone of an immortalized human B memory lymphocyte capable of producing a human monoclonal antibody with a desired antigen specificity, comprising the steps of: (i) selecting and isolating a human memory B lymphocyte subpopulation; (ii) transforming the subpopulation with Epstein Barr Virus (EBV) in the presence of a polyclonal B cell activator; (iii) screening the culture supernatant for antigen specificity; and (iv) isolating an immortalized human B memory lymphocyte clone capable of producing a human monoclonal antibody having the desired antigen specificity.